About
Technology
Issues
FAQ
Links
Official Page
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.